💧 GU Oncology — 2026-W44

What this page is. Every paper the week's monitor reviewed — including the ones that did not go into the digest. Material marked “Not selected” was reviewed and deliberately left out. It has not been fact-checked to digest standard and is not endorsed. For the curated read, see the digest itself.

Double-blind phase 3 RCT of perioperative pembrolizumab vs placebo added to neoadjuvant cisplatin-gemcitabine in cisplatin-eligible muscle-invasive bladder cancer, published in Annals of Oncology. Informs whether adding perioperative PD-1 blockade to chemotherapy and cystectomy improves event-free survival, with results to be weighed against other perioperative regimens.

Updated ad hoc survival analysis of the phase 3 CAPItello-281 RCT of capivasertib plus abiraterone in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer, published in Annals of Oncology. Provides more mature overall survival data to help judge the role of this combination in this biomarker-selected population.

Open-label phase 3 RCT in high-risk localized or locally advanced prostate cancer, published in J Clin Oncol. Adding enzalutamide to radiotherapy plus ADT did not significantly improve metastasis-free or overall survival, with a possible benefit in the pelvic nodal radiotherapy subgroup that is hypothesis-generating.

Phase 3 RCT (ENERGIZE) in previously untreated cisplatin-eligible muscle-invasive bladder cancer, published in Annals of Oncology. Adding perioperative nivolumab to neoadjuvant gemcitabine-cisplatin did not improve event-free survival, so it does not support this combination as a new standard.

Pan-Asian adapted ESMO clinical practice guideline for renal cell carcinoma diagnosis, treatment and follow-up, published in ESMO Open. Provides expert consensus to harmonize RCC management across Asian countries independent of drug access and reimbursement.

Nationwide retrospective target-trial-emulation cohort in bone-metastatic castration-resistant prostate cancer, published in JAMA Netw Open. Informs how long to continue denosumab, balancing osteonecrosis of the jaw risk against skeletal event protection.

Cross-sectional analysis published in JAMA Network Open examining oral targeted therapy prescribing and urologist-medical oncologist comanagement in advanced prostate cancer. Informs care delivery patterns rather than changing treatment decisions.

Exploratory, placebo-controlled, nonrandomized phase 2a trial of neoadjuvant nivolumab with or without the GDF-15 antibody visugromab in cisplatin-ineligible muscle-invasive bladder cancer, published in Nature Medicine. Suggests GDF-15 blockade may improve responses to PD-1 therapy, warranting larger confirmatory study.

Retrospective single-center cohort in advanced urothelial carcinoma receiving first-line enfortumab vedotin plus pembrolizumab, published in JAMA Network Open. Examines whether early skin toxicity is associated with survival outcomes, informing toxicity counseling and management during treatment.

Retrospective real-world cohort of metastatic hormone-sensitive prostate cancer from the Flatiron database, published in JAMA Network Open. Compares intensification with abiraterone versus androgen receptor inhibitors on overall survival, informing treatment choice absent head-to-head randomized trials.

Economic evaluation (Markov decision model) of perioperative enfortumab vedotin plus pembrolizumab versus cystectomy alone in cisplatin-ineligible muscle-invasive bladder cancer, published in JAMA Network Open. Informs value and access discussions for this regimen but does not change clinical efficacy evidence.

Systematic review and meta-analysis of retrospective studies in cT1 micropapillary bladder cancer, published in European Urology Oncology. Compares bladder-sparing approaches such as BCG with early cystectomy, informing counseling in this variant histology though limited by retrospective data.

Preclinical translational study in prostate cancer models and human specimens, published in Nature Communications. Proposes NCOA6 loss as a biomarker for EGFR-inhibitor sensitivity, but this is hypothesis-generating without clinical treatment data.

Exploratory retrospective translational analysis within a CAR-T trial in metastatic castration-resistant prostate cancer, published in J Immunother Cancer. Suggests circulating tumor cell clonal dynamics may track response, but the small cohort makes it hypothesis-generating.

Retrospective multicenter cohort in pretreated advanced urothelial carcinoma, published in JAMA Network Open. Examines whether physician-selected reduced starting doses of enfortumab vedotin affect efficacy and neuropathy, informing dosing decisions in practice.